Skip to main content

Advertisement

Understanding aneuploidy in cancer through the lens of system inheritance, fuzzy inheritance and emergence of new genome systems

Article metrics

Abstract

Background

In the past 15 years, impressive progress has been made to understand the molecular mechanism behind aneuploidy, largely due to the effort of using various -omics approaches to study model systems (e.g. yeast and mouse models) and patient samples, as well as the new realization that chromosome alteration-mediated genome instability plays the key role in cancer. As the molecular characterization of the causes and effects of aneuploidy progresses, the search for the general mechanism of how aneuploidy contributes to cancer becomes increasingly challenging: since aneuploidy can be linked to diverse molecular pathways (in regards to both cause and effect), the chances of it being cancerous is highly context-dependent, making it more difficult to study than individual molecular mechanisms. When so many genomic and environmental factors can be linked to aneuploidy, and most of them not commonly shared among patients, the practical value of characterizing additional genetic/epigenetic factors contributing to aneuploidy decreases.

Results

Based on the fact that cancer typically represents a complex adaptive system, where there is no linear relationship between lower-level agents (such as each individual gene mutation) and emergent properties (such as cancer phenotypes), we call for a new strategy based on the evolutionary mechanism of aneuploidy in cancer, rather than continuous analysis of various individual molecular mechanisms. To illustrate our viewpoint, we have briefly reviewed both the progress and challenges in this field, suggesting the incorporation of an evolutionary-based mechanism to unify diverse molecular mechanisms. To further clarify this rationale, we will discuss some key concepts of the genome theory of cancer evolution, including system inheritance, fuzzy inheritance, and cancer as a newly emergent cellular system.

Conclusion

Illustrating how aneuploidy impacts system inheritance, fuzzy inheritance and the emergence of new systems is of great importance. Such synthesis encourages efforts to apply the principles/approaches of complex adaptive systems to ultimately understand aneuploidy in cancer.

Background and progress

Why is aneuploidy commonly observed in various cancer types? How does aneuploidy directly or indirectly contribute to cancer? Is aneuploidy good or bad for cancer initiation and progression, and how does it affect treatment response? What is the relationship between aneuploidy and other genetic/epigenetic aberrations? How important is it to study each individual molecular mechanism that can be linked to aneuploidy? What are the general mechanisms (cause and effect) for generating aneuploidy? Why can aneuploidy be detected from other diseases? And what is the biological significance of aneuploidy in normal tissues for normal individuals? … These questions represent some long-debated issues in the field of cancer research, ever since Theodor Boveri recognized the link between aneuploidy and cancer over a century ago [1,2,3,4].

Specific aneuploidy has been observed in various non-cancer diseases: Down syndrome with trisomy chromosome 21, Edwards syndrome with trisomy 18, Patau syndrome with trisomy 13, Klinefelter’s syndrome with an extra X, and Turner’s syndrome with the absence of one X. While clonal aneuploidy is also detected in some cancers, such as chronic lymphocytic leukemia (CLL) with trisomy 12 and acute myeloid leukemia (AML) with trisomy 8, the percentage of such cancer patients with the signature clonal aneuploidy is much lower (18% for CLL and 8.5% for AML) compared to those with Down syndrome (over 95% of all patients), suggesting that there are more diverse genomic factors contributing to cancer (even for the liquid cancer type) than those non-cancer genetic diseases.

Altogether, the complexity of aneuploidy makes studying its relationship with cancer extremely challenging (Table 1). Some known complications include: a) most cancer cases display non-clonal aneuploidy (impeding the fact that clonal aneuploidy has been much more commonly researched for decades) [5,6,7,8,9], b) aneuploidy often occurs in combination with other types of genetic/epigenetic and genomic aberrations (translocations and polyploidy) (Table 2) c) there is often a variable degree of somatic mosaicism [10,11,12,13], and d) there is a complex, dynamic relationship between aneuploidy and genome instability (Table 3). Interestingly, many common and complex diseases have been linked to non-clonal aneuploidy and somatic mosaicism as well [14, 15], which has led to efforts to search for commonly shared mechanisms among different diseases or illness conditions [16,17,18,19]. It is worth noting that aneuploidy can also be detected from the normal developmental process [20,21,22].

Table 1 Explanations of key terminologies
Table 2 Examples of different types of causative factors of aneuploidy
Table 3 Examples of interesting observations in aneuploidy studies including some conflicting data.  Some comments are also offered to explain them

Such complexity did however discourage aneuploidy research, as cloning and characterizing individual cancer genes had promised much more certainty. During the peak era of oncogene- and tumor suppressor gene-focused research, for example, the importance of aneuploidy was largely ignored, due to high expectations from the gene mutation theory of cancer. As a result, efforts to systematically study aneuploidy in cancer, especially based on the belief that aneuploidy is much more important than gene mutations, are limited to a small number of research groups [23,24,25,26]. One of the popular viewpoints was that cancer gene mutations hold the key to understanding cancer, whereas chromosomes were just vehicles of genes; it was furthermore argued that most chromosomal changes are either incidental or the consequence of gene mutations.

While it was observed that some chromosomes display a tumor suppressor function following cell/chromosome fusion experiments [27], efforts were focused on cloning tumor suppressor genes [28]. The lack of easy-to-recognize patterns in aneuploidy has certainly reduced the enthusiasm of most funding agents about this topic, especially when gene mutation research has promised to identify the key common gene mutations for cancer.

One important publication has classified cancer into two major types based on observed molecular mechanisms: chromosome instability (CIN) and microsatellite instability [29]. Remarkably, the majority of colon cancers display CIN. The fact that most cancers can be linked to chromosomal instability was a surprise to many who primarily study cancer genes.

If the majority of cancers are linked to CIN, and aneuploidy contributes to CIN, more attention needs to be paid to aneuploidy [30]. Based on this concept, increased efforts were focused on identifying genes that are responsible for aneuploidy. Many individual genes and molecular pathways involving chromosomal machinery/integrity have been linked to aneuploidy. For example, a list of identified genes that contribute to aneuploidy-mediated cancer includes germline BUBR1 mutation, which leads to aneuploidy and cancer predisposition [31]. Additional examples can be found in Table 2.

Another important factor that promotes aneuploidy research is the popularization of copy number variation studies of the human genome [32,33,34]. If various individual instances of CNV are of importance, large scale CNVs caused by aneuploidy should be too, despite the fact that the search for specific genes related to aneuploidy (such as chromosome 21) have traditionally been the main focus. The availability of various technologies that can detect CNV have now revolutionized molecular cytogenetics. It should be mentioned that the cytogenetically visible copy number variations (CG-CNVs) need more attention [35]. Regarding the framework of fuzzy inheritance, CNVs, CG-CNVs, small supernumerary marker chromosomes and aneuploidy represent different degrees of fuzziness, which are likely reflected by quantitative difference or combinational effect. It is important to integrate these with analyses of system emergence [4, 36, 37].

In recent years, due in part to the disappointment that has come from attempting to identify the common driver gene mutation, and more significantly, due to the realization that genome instability plays an important role in cancer, aneuploidy studies have gained momentum. In particular, the popularity of studying aneuploidy in cancer has been promoted by some yeast biologists. Taking advantage of yeast model systems, they have applied cutting-edge molecular and genomic technologies to illustrate the molecular mechanisms that link aneuploidy to biological functions [38,39,40,41,42]; by translating their discoveries into cancer research, they have brought the spotlight on aneuploidy research in cancer [43, 44] (Tables 2, 3). Interestingly, a complex relationship between aneuploidy and cancer has also been revealed, proposing that aneuploidy can either promote or inhibit cancer progression depending on the evolutionary context. This has led to the paradox of aneuploidy in cancer [45, 46].

There have been attitude changes towards the study of aneuploidy as well. When direct evidence simultaneously characterized gene mutation and chromosomal aberrations as drivers for the phenotypic implication of metastasis [47], the authors clearly emphasized CIN, and the potentially involved gene was not even mentioned in the title. This likely represents a new favored approach focusing on genome-level changes. There is also the realization that chromosomal aberrations contribute more significantly to metastasis than gene mutations do [48] which supports the hypothesis that chromosomal aberration-mediated genome evolution is responsible for all major transitions in cancer evolution, including metastasis and drug resistance [49, 50]. Furthermore, and surprisingly to many molecular researchers, chromosome aberration profiles have been demonstrated to have a much stronger prediction value in the clinic compared to DNA sequencing profiles [51]. This conclusion has gained strong support from various cancer genome sequencing projects [52, 53], which prompts an important question regarding the differential contribution of chromosome aberrations and gene mutations to the cancer genotype. All together, rapidly accumulated data has forcefully highlighted the importance of aneuploidy in current cancer research, and more detailed molecular information linking individual gene mutations or epigenetic events to aneuploidy will soon flourish.

Challenges for predicting cancer status based solely on the molecular mechanisms of aneuploidy

Like other hallmarks of cancer, aneuploidy has now become a hot topic. A predictable new trend is that more researchers will join the effort to link all possible genetic/epigenetic and environmental factors to aneuploidy and cancer. However, as we have extensively discussed, due to biocomplexity (i.e. that many individual factors can contribute to the same phenotype), it is possible that merely collecting more diverse molecular data linking gene mutation and environmental factors to aneuploidy is not the best way to advance this field. This is because there will be too many factors involved, most of them lacking the power to predict cancer status [54, 55].

This viewpoint has been articulated by the evolutionary mechanism of cancer and its relationship with individual molecular mechanisms [50, 56]. In brief, cancer evolution can be understood by the dynamic interaction among four key components: internal and external stress; elevated genetic and non-genetic variations (either necessary for cellular adaptation or resulting from cellular damages under stress); genome-based macro-cellular evolution (genome replacement, emergent as new systems); and multiple levels of system constraint which prevent/slow down cancer evolution (from tissue/organ organization to the immune system and mind-body interaction). Since the sources of stress are unlimited and unavoidable (as they are required by all living systems), there are large numbers of gene mutations/epigenetic events/chromosomal aberrations, such as aneuploidy, that can be linked to stress-mediated genomic variants; furthermore, as environmental constraints are constantly changing, even identical instances of aneuploidy will have completely different outcomes in the context of cancer evolution, as the results of each independent run of evolution will most likely differ. Solely knowing the mechanism of aneuploidy limits the predicting power for cancer. Furthermore, hundreds of gene mutations can contribute to aneuploidy, and the various contexts of cancer evolution are almost unlimited. Based on this rationale, we promote the idea of using the evolutionary mechanism of cancer to unify diverse individual molecular mechanisms of cancer (4).

Unfortunately, such ideas have received little attention within the cancer research community, due in part to the traditional molecular characterization of gene mutations, and possibly more so due to many cancer biologists’ unfamiliarity with complexity science and a lack of understanding of the key principles of bio-emergence. It is thus necessary to discuss this issue of aneuploidy in cancer using the framework of the complex adaptive system [37].

A complex adaptive system is a system made up of many individual parts (agents) with nonlinear dynamical interaction. Due to the key emergent relationship between the lower level of heterogeneous agents and the behavior of the entire system, a detailed understanding of the individual parts does not automatically convey a determinist’s understanding of the whole system’s behavior. There are no fixed, dominant agents within the adaptive system, and when agents of the system are changed, the system adapts or reacts. Moreover, small changes in initial conditions can generate large changes in the system’s outcome, and stochasticity is also frequently involved [57, 58]. As a result, the reductionist approaches which have triumphed in molecular biology may be fundamentally limiting when attempting to understand complex adaptive systems.

Cancer is typically a complex adaptive system involving multiple levels of agent interactions and genotype/phenotype emergence among different types of tissue/organ constraints. In such a system, aneuploidy represents only one type of agent, despite its importance. There is a complex interaction among different levels of genetic organization, which involves phase transitions among clonal and non-clonal cellular populations, and the final emergence of different genome-defined cellular systems under highly dynamic cellular environments and the process of cancer evolution. This reality of cancer evolution explains why it is so challenging to predict the final phenotype based on an understanding of one type of agent. The take-home message is that simply understanding the molecular mechanism (both cause and effect) of aneuploidy is far from enough. A better strategy is to monitor the evolutionary process by measuring evolutionary potential. For example, the overall degree of CIN is more predictive than individual gene mutation profile [54]; large-scale chromosomal structural aberrations can often have a more profound impact on cancer evolution (even though aneuploidy often leads to structural aberrations as well); and the landscape of chromosomal aberrations is more predictive than gene mutation landscapes. Furthermore, the initial factor and the evolutionary trajectory differ in complex systems. It is now accepted that treatment options can often drastically and rapidly change the genetic landscape of the cancer [59].

In addition to the challenge that cancer is a complex adaptive system, it should be understood that current molecular knowledge of aneuploidy is mainly derived from model systems, which can differ from cancer systems in patients. The following limitations are briefly mentioned to bring the reader’s attention to them, and they are also useful for explaining some conflicting observations. First, the platform of the yeast model differs from human cellular populations within tissue. Different species display the feature of aneuploidy quite variably. In budding yeast Saccharomyces cerevisiae, aneuploidy is not uncommon and exists in natural populations; in plants, organisms can tolerate whole chromosome aneuploidy without triggering CIN; in mice, every single whole chromosome gain or loss is embryonic lethal [60]; in humans, the situation is similar to that of mice, with the exception of a few chromosome gains such as 13, 18 and 21. The pattern of evolution also differs when diverse types of cellular selection are involved, in addition to differing types of system constraints. For cancer evolution in reality, the overall complexity and the level of dynamics is much higher, which can often change the game completely. In the future, multiple cellular models might be helpful to certain degrees, especially when the time variable (i.e. development and aging) is added in to the equation.

Second, the status of clonal and non-clonal aneuploidy differs between many model systems and the reality of cancer. So far, for many yeast and human cell models, aneuploidy stains are created with clonal populations in which most cells display the same extra chromosomes. In contrast, for many solid tumors, aneuploidy exists in non-clonal forms. Such differences may contribute to some misperceptions, thus requiring further studies. For example, the analysis of trisomic cells from human patients with congenital aneuploidy syndromes did not display any increased CIN, concluding that aneuploidy itself does not lead to cancer-like CIN [61]. We have mentioned the significant difference between constitutional aneuploidy and the acquired aneuploidy observed in cancers. Constitutional aneuploidy is a clonal-chromosome aberration (CCA), whereas many acquired somatic aneuploidies are nonclonal-chromosome aberrations (NCCAs). In the cellular environment of trisomy 21, trisomy 21 is the dominating “normal” genome, and any other genomes (including the “normal” 46 XY or XX karyotype) are relatively “abnormal;” the homeostasis of trisomy 21 could actually generate less cellular variation, which explains the resulting low levels of cell-to-cell variations. Based on this analysis, we suggested that although specific constitutional aneuploidy alone is not sufficient for generating numerical CIN, it is necessary to examine the impact of non-recurrent, stochastic aneuploidy on generating all types of CIN [62].

Third, many models feature simple types of aneuploidy (with one extra chromosome within an otherwise normal karyotype, for example), which is easier to analyze with repeatable results. In contrast, in the setting of cancer evolution, aneuploidy is often coupled with structural chromosomal changes and/or polyploidy. In addition, the rate of aneuploidy within the population is often lower than in clonal populations of model systems, while for each cell with aneuploidy, the heterogeneity is higher than cells from model systems (there are often multiple extra chromosomes, for example). Such differences between model systems (in which the majority of cells are isogenic) and cancer samples (which have high levels of chromosomal and gene mutation heterogeneity) are reflected by the display of mainly micro-evolutionary processes in model systems, and a mixture of macro-evolution plus micro-evolution in real cancer. In a sense, many model systems mimic a population of the same species, while real cancer systems mimic a population of the same species and different species [4, 63,64,65].

Fourth, when discussing the advantages/disadvantages of aneuploidy, the majority of studies are focused on growth status. It should be pointed out that while growth represents a key feature of cancer, during the earlier stages of cancer evolution, growth might not necessarily be the key precondition. The rationale of focusing on cell proliferation in cancer research was based on the concept of accumulating gene mutations during cancer initiation and progression; it was thus argued that the proliferated cell population could provide the basis for stepwise cancer evolution. Since the discovery that punctuated cancer evolution is achieved by genome reorganization events, such as genome chaos, the rationale of focusing on proliferation has been challenged [6,7,8, 50, 56, 66, 67]. Surely, the cancer genome sequencing project has failed to detect serial, stepwise gene mutation accumulation in the majority of cancer cases [4, 59, 68]. In contrast, system instability might not only be an important earlier event, but in fact the key event. According to the genome theory [4, 49, 50, 56], genome instability could be the key driver for all major transitions for cancer evolution, including transformation, metastasis, and drug resistance. It is likely that cellular proliferation contributed by the “oncogenes” often represents the later events which help cancer cells to become more dominant cell populations (for more, see reference [4, 37]). Similar patterns have been observed in metastasis and drug resistance. Therefore, system instability might be the most important aspect for the success of cancer: new systems’ emergence from normal tissue [69, 70]. Recent single-cell sequencing of breast cancer cells supports this viewpoint. It was observed that copy number changes and rearrangements appeared early in tumorigenesis. In contrast, point mutations occurred gradually during tumor evolution (within the micro-evolutionary phase) [71].

Fifth, most current research efforts are focusing on molecular profiles based on an average population, and outliers are eliminated or ignored, either by the methods used or statistical tools. The traditional view of biological research is to identify patterns from “noise,” without the realization that the so-called “noise” in fact is heterogeneity, which represents a key feature of cancer evolution by functioning as the evolutionary potential. Increased studies have demonstrated the importance of outliers in cancer evolution, as cancer is an evolutionary game of outliers [4, 72, 73].

Sixth, in the search for the molecular consequence of aneuploidy, the focus is still on the genes’ function. Despite the fact that it is hard to make sense out of the data of altered profiles of a large numbers of genes, few have realized that aneuploidy, in fact, changes a new chromosomal-level coding system, which is namely the system inheritance [16, 37, 66].

Clearly, a new framework is needed to systematically study aneuploidy in cancer evolution. Since cancer is a complex adaptive system, and each run of successful evolution can be linked to different genome and gene mutation profiles, more attention needs to be paid to the gap between initial conditions and final emergence, the environmental and genome contexts, landscape dynamics, and system instability-mediated cancer evolutionary potential [59]. Because cancer evolution requires inheritance, and involves the emergence of new systems, the following session will focus on these issues to redefine inheritance and the emergent bio-cellular system.

The genome theory of cancer evolution

Based on the ultimate importance of chromosomal aberrations in cancer evolution, especially within the punctuated phase of macro-cellular evolution, the genome theory of cancer evolution was introduced with the aim of departing from the gene mutation theory of cancer [4, 49, 66]. To illustrate how chromosomal changes play a key driving role in cancer evolution, we have redefined the genomic meaning of karyotype changes, and compared the evolutionary dynamics between clonal and non-clonal chromosomal aberrations [6,7,8, 64, 74]. Moreover, we have proposed the use of the genome-mediated evolutionary mechanism to unify the diverse molecular mechanisms of cancer [55, 75]. Since aneuploidy represents one important type of karyotype aberration [15, 74], the principles of genome theory can be easily applied to aneuploidy research in the context of somatic evolution, complexity, and how chromosomally-defined new genomic information plays a driving role for new system emergence.

System inheritance and aneuploidy

Genes encode proteins, and the sequence of ATGC within genes is the genetic coding. It has been challenging to study how aneuploidy affects genetic coding when there are over a thousand genes involved. Traditionally, attention has been paid to dosage effects. With the development of the technical platform for transcriptome profiling, it was surprisingly observed that the impact of aneuploidy is far beyond the dosage effect on genes located on gained or lost chromosomes [40, 76, 77]. Even more interestingly, different experimental systems differ in terms of the observed impact. The genomic basis for these unexpected findings is unknown.

During our watching-evolution-in-action experiments within an in vitro immortalization model, we constantly observed rapid and massive genome re-organization during the punctuated phase of cancer evolution [4, 6,7,8, 78]. Remarkably, during this phase, mother cells can generate daughter cells with similar DNA but drastically different karyotypes. To illustrate the biological meaning of this karyotype re-organization, we realized that the shattering of the genome and its subsequent reorganization represent a powerful means of creating new genomic information. Such a new mechanism functions above the coding of individual genes, and perhaps serves to organize gene interaction.

One of the biggest promises of the human genome sequencing project was to decipher the blueprint that makes us human. Unfortunately, we have failed to achieve this goal following the sequencing phase of the genome project. Despite that we know the sequence of nearly all genes, we have no idea what the genomic blueprint is. Systems biologists have suggested that the network structure defines the blueprint. But what defines the network structure in the first place?

Putting all of these questions together, we realized that the karyotype, in fact, represents a new genomic coding system, and the blueprint is encoded by the new genomic information which is defined by the order of genes along and among chromosomes [4, 37, 59]. More specifically, a gene only encodes a specific “part inheritance,” while a set of the chromosomes of a given species encodes the “system inheritance” [16, 66]. Furthermore, we suggested that the karyotype defines the boundary of a network structure for a given species, which integrates the network into the genome-defined system [69, 70].

Further studies suggested that karyotype coding is maintained by the function of sex through the meiotic pairing mechanisms [79,80,81,82]. Nearly all significant karyotype aberrations will be eliminated by the “reproductive filter,” which ensures the species identity. In this way, similar gene content can form different species by creating different karyotypes, which determine the physical platform for gene interactions in the 3-D nucleus [37]. Since different species display different karyotypes, a species is in fact preserved by its own chromosomal coding. Furthermore, it is likely that altered genomic information contributes to many common and complex diseases [4, 37].

Obviously, aneuploidy alters the karyotype and thus changes the genomic coding. Despite the fact that much work is needed to illustrate the details of how aneuploidy changes genomic coding, many experiments support this idea in principle. For example, aneuploidy not only changes the overall transcriptomes, but can specifically provide new functions to rescue cells lacking specific essential genes. When the only copy of the MYO 1 gene was knocked out, yeast should no longer have been able to survive, as MYO1 encodes the myosin II protein required for cytokinesis. Surprisingly, however, extensive polyploidy and aneuploidy (rather than reverse mutation) was demonstrated to rescue the dying populations, illustrating that genome-level changes can generate emergent new phenotypes without directly fixing the specific deleted gene [83]. In other words, re-organizing the karyotype coding can create functions encoded by specific genes in different systems. Ample evidence can be found in current literature [4, 37].

Fuzzy inheritance and aneuploidy

One key feature of cancer is its multiple levels of genetic/epigenetic/genomic heterogeneity. During time-course experiments designed to trace karyotype evolution in vitro, it was documented that the degree of karyotype heterogeneity can be drastically different depending on the phases of cellular evolution [6,7,8]. In addition, the different extents of karyotype heterogeneity are evolutionary phase-specific (extremely high within the punctuated phase and low within the stepwise phase), suggesting that karyotype heterogeneity is inheritable among different cell populations. A similar phenomenon has been observed from DNA mutation when discussing the mutant type [84]. Recently, the two phases of cancer evolution have been confirmed by gene mutation and copy number profiling [71, 85,86,87,88].

Following the characterization of various cancer cell lines, it became clear that each line displays a different degree of heterogeneity (reflected as the rate of NCCAs). To establish the baseline of karyotype heterogeneity in normal individuals, SKY karyotype analysis was used after short-term culture of lymphocytes, and the rate of structural NCCAs was found to be around 1–4%. Interestingly, drug treatment-induced frequencies of NCCAs are also different among cell lines or individuals with different levels of genome instability, and elevated frequencies of NCCAs from lymphocytes are detected from various diseases or illness conditions [17, 19, 89].

The above observations are highly significant in the context of missing inheritability [90, 91]. It is generally accepted that phenotype is the result of the interaction of genotype and environment, but its mechanism is not clearly understood. For example, for phenotype plasticity, the mechanism is unknown. It is also unclear how different genotypes display different extents of phenotypic plasticity, and why environment can win over the power of genetics or vice versa.

The link between the frequency of NCCAs and phenotype heterogeneity has promoted the concept that the previously regarded “noise,” in fact, represents karyotype heterogeneity. Further research/synthesis has led to the realization that it is likely that the coded message at the karyotype level is heterogeneous in nature, which results in high phenotypic plasticity.

Important questions were then asked. Is it possible that inheritance itself is not precise but fuzzy, even for the coding of a single gene-determined phenotype? Do genetic elements code a spectrum of potential information rather than a fixed one? What if these highly penetrant relationships between genotype and phenotype only represent exceptions in which environmental factors are well-controlled? Does the major role of environmental factors select a specific possibility encoded by the genetic coding? Do stress conditions increase the heterogeneity of phenotype by increasing the fuzziness of the genetic coding? To address these questions, fuzzy inheritance has been introduced by us as the mechanism of various levels of genetic and epigenetic heterogeneity [4, 37, 70].

Since non-clonal aneuploidy belongs within the category of NCCAs and represents karyotype heterogeneity, it is important to integrate aneuploidy into fuzzy inheritance. Despite the fact that the frequencies of aneuploidy in various normal tissues are low, when combined with other NCCAs, the level of altered karyotypes is rather high, especially under stress conditions [50, 92, 93, 94]. In addition, the drastic difference between the spontaneous rate of aneuploidy in cells from normal tissue and in those from cancers supports the idea that specific cell populations display different degrees of fuzzy inheritance which are related to aneuploidy. For example, the mis-segregation rate in a stable, diploid cell line is one chromosome per 100–1000 cell divisions. In contrast, the mis-segregation rate in cultured cancer cells with CIN is approximately once every 1–5 divisions [95,96,97]. More remarkably, during the genome chaos phase, almost all cells display a high rate of mis-segregation with large number of aneuploidies, plus all sorts of karyotype variants [6, 50, 67]. The high degree of fuzzy inheritance in cancer, in fact, can also explain why non-clonal aneuploidy is a common feature of even later stages of cancer. All tumors are under high stress from surrounding tissues or higher systems, so fuzzy inheritance-mediated karyotype heterogeneity is essential for tumor survival and further progression. Clearly, how aneuploidy quantitatively contributes to fuzzy inheritance-mediated genomic heterogeneity needs further study.

The relationship between cellular adaptation and trade-off

Traditionally, aneuploidy has long been blamed as the result of bio-errors. Most of the molecular evidence supports this viewpoint, as when specific genes are dysfunctional as a result of experimental manipulation, a phenotype of increased aneuploidy can be observed. Many gene mutations involving cell cycle/chromosomal integrity can achieve the same phenotype. While the baseline of aneuploidy in normal individual tissues is low in many cases, in some tissue types, the spontaneous aneuploidy is high. Moreover, the overall rate of NCCAs is not low at all in most normal tissues.

Obviously, the higher than expected frequency of karyotype changes, including aneuploidy, cannot simply be explained as bio-error. In recent years, the biological significance of these seemingly random genetic “backgrounds” were studied, which has led to the appreciation of genomic heterogeneity in cancer evolution. Further synthesis suggests a relationship between stress-induced NCCAs and the advantages offered by their presence for cellular adaptation, as well as the trade-offs caused by their presence in cancer evolution and possibly in other disease conditions [4, 92]. Moreover, many diseases are the results of genomic variants which do not fit the current environments. Due to the dynamics of environments and the nature of fuzzy inheritance, it is impossible to eliminate all of these variants. Paradoxically, these genomic variants might be necessary for the species’ long-term survival, and they should be considered as a life insurance policy despite their high costs. Such a concept of trade-off not only addresses the key evolutionary mechanism of many diseases including cancer, but may also provide some answers to patients who ask the “why me” question. In a sense, cancer as an evolutionary trade-off can be illustrated by different perspectives: at the mechanistic level, cancers are the by-products of evolution (that is, the same mechanisms which make us human also make cancer successful); at the species level, as population heterogeneity is important for species survival, an individual with high genome instability can be considered as paying the price for our species; and at the individual level, most bio-features, including lifestyle, could be beneficial in some aspects and yet harmful in other aspects. Even for non-clonal aneuploidy-mediated cellular heterogeneity, while this phenomenon can provide a potential advantage for cellular adaptation, it can also, paradoxically, generate non-specific system stress, which can further produce more genetic and non-genetic variants which favor the disease condition [4]. Based on this rationale, we have attempted to use type I and type II CIN to unify diverse gene mutations under the principle of CIN-mediated cancer evolution, as many gene mutations and molecular pathways which are not directly involved in maintaining genome integrity can still be linked to CIN [50].

Emergence and luck

The unpredictability of emergence represents a common challenge for using parts characterization to predict phenotype at higher levels in a complex adaptive system. How aneuploidy triggers the successful evolution of cancer, especially during the phase transitions, is almost unknown. The situation worsens when the type of aneuploidy is non-clonal, and when both the context of other types of genetic changes and cellular environments keeps changing. For example, different tissues can tolerate different degrees of aneuploidy; aneuploidy can be detected at the early development stage with high frequencies, but the developmental process can overcome them, whereas the impact of aneuploidy can become serious during cancer evolution later in life; even in tissues that are sensitive to aneuploidy, most instances of aneuploidy will not lead to cancer. It seems that in different tissue types, different stages of development and aging, and different physiological and pathological processes, there are different “roles” for the cellular society which favor different types of emergence [19, 37]. For example, in a normal physiological cellular society, the average profile can overrule outliers, while in the setting of cancer evolution and under high stress, the outliers may triumph.

To understand how non-clonal karyotype aberrations can contribute to the emergence of cancer evolution, we proposed that instances of non-clonal aneuploidy, like other types of non-clonal karyotype aberrations, serve as heterogeneous agents that can impact the emergent properties of the cellular evolution. While the details of how aneuploidy affects emergence are not yet known, this model illustrates the importance of how even a portion of non-clonal aneuploidy can change the emergence process (Fig. 1). A similar general model of how the heterogeneity of genetic agents impacts diseases has been proposed to explain how NCCAs can contribute to different diseases [18, 98].

Fig. 1
figure1

The illustration of how the heterogeneity of aneuploidy impacts the emergent properties of cellular populations. Since there is no direct correlation from individual agents to the emergent properties, the final properties are based on the collective emergence of all agents. Circles represent cells with normal karyotypes, triangles represent cells with non-clonal aneuploidy, and arrows represent pathways among agents. These variable properties are the potential basis for cancer evolution (modified from reference [19])

Due to the complex combinations of aneuploidy and the genetic and environmental contexts, a vast majority of these combinations will not directly lead to cancer’s success, as they are either not powerful enough to contribute to the phase transition which leads to cancer, or they are eliminated by system constraint. For example, it was recently demonstrated that the complex karyotypes derived from aneuploidy can trigger the immune system to eliminate them (Table 3). Another example is drug therapy in which a high dosage of drugs is used. The majority of the cancer cells will be eliminated by the initial drug treatment, and only a tiny portion of the cancer cells can survive (through the formation of genome chaos). It is extremely challenging to predict which aberrations will be successful, even though drug-resistant clones often arise.

As a consequence of the highly heterogeneous nature of karyotypes featuring aneuploidy, as well as the diverse genomic/environmental contexts involved, most genomic aberrations will not lead to the success of cancer, despite their potential. A “perfect storm” is needed for any cancer to be successful. Under such conditions, luckiness or unluckiness can be considered agents which impact the emergent properties.

Such interplay during cancer evolution is ultimately responsible for the emergence of a new genome system from normal tissue, and aneuploidy-mediated genome re-organization plays a key role for creating these new systems [4, 37, 66]. For altered cells to become cancer cells, they have to complete many key transitions, including immortalization, transformation and metastasis, all of which require the emergence of different genome systems; gene mutation alone is not sufficient for creating a new system. The alteration of system inheritance and the increased degree of fuzzy inheritance mainly contribute to the macro-cellular evolution which leads to new systems. In contrast, genes that promote cell proliferation can expand cancer cell populations following the formation and selection of cancer cells with unique karyotype-defined systems (Fig. 2).

Fig. 2
figure2

The proposed timeline that illustrates the relationship between various molecular mechanisms (summarized by the hallmarks of cancer, modified from reference [50, 139]), aneuploidy, CIN (often coupled with other karyotype alterations such as structural alterations and polyploidy), macro-evolution, micro-evolution and the clinically detectable tumor. As NCCAs can be detected from earlier developmental stages, the relationship between various molecular mechanisms and aneuploidy is less clear. It is clear, however, that there is a complex, interactive relationship. Furthermore, elevated CIN is important for triggering macro-cellular evolution, followed by micro-cellular evolution, leading ultimately to the proliferation of the cancer cells with the winning genome. This diagram highlights the complex, dynamic relationship between aneuploidy, CIN and the two phases (macro and micro) of cancer evolution

Conclusion and future research

Within the framework that represents cancer as a complex adaptive system, the following elements become highly important for understanding both the key feature and common mechanism of cancer: internal and external stress-mediated adaptation and its trade-off (trigger factors); the multiple levels of genetic/environmental heterogeneity (essential conditions for cancer evolution); the involvement of system inheritance and fuzzy inheritance (how genomics works during cancer evolution); the two phases of cancer evolution (the mechanism of cellular evolution and the relationship between gene/epigene and genome changes); the emergence of new, karyotype-defined systems (the formation of a cancer seed and the importance of NCCAs and outliers); and the population of cancer cells that become clinically significant (the dominance of cancer). It is necessary to integrate these elements during studies of aneuploidy.

Despite the recent exciting progress of aneuploidy research, some great challenges remain. Simply focusing on the molecular characterization of agents at lower levels is neither sufficient for understanding the emergent properties of a complex adaptive system nor for predicting the contribution of aneuploidy to cellular evolution.

To change the status quo, the crucial first step is to acknowledge the fundamental limitation of the reductionist approach in aneuploidy research, as there is no precise, predictable relationship between an understanding of the individual mechanism of aneuploidy and clinical certainty, nor between many diverse individual agents and the emergent properties of cancer evolution. It is thus equally difficult to search for patterns based on diverse molecular pathways. In addition, the dynamic interaction of average cells and outliers further complicates this prediction. To make sense of this complexity and to increase predictability, a better strategy is to consider aneuploidy as an agent and cancer as a complex adaptive system. Expectations regarding the predictive power of aneuploidy must also change, as the success of cancer evolution depends on both evolutionary potential (which can be measured) as well as on chance or accidents (which are hard to predict) [99, 100]. The importance of special “circumstances” or “accidents” in evolutionary success is receiving our increased attention [4, 37, 66].

An innovative type of biomarkers is needed to integrate aneuploidy with other karyotype alterations, and these should be used to measure evolutionary potential (based on the degree of heterogeneity and karyotype complexity) rather than specific pathways. This approach will likely bridge the gap between basic research and clinical implications. There are some examples of applying aneuploidy in clinical analysis [101]. High somatic copy number alterations in melanoma patients have recently been linked with less effective response to immune checkpoint blockade anti–CTLA-4 (cytotoxic T lymphocyte–associated protein 4) therapy [52]. Clearly, aneuploidy status is associated with response to precise immunotherapy. We have engaged in the effort of using NCCAs (mainly structural NCCAs) to monitor clinical outcomes. One approach is to measure an individual’s overall genome instability and its linkage to cancer status. We have observed a strong correlation between the frequencies of structural NCCAs from short term lymphocytes culture and prostate cancer [37]. This work has expanded into other health conditions [17]. A similar concept of monitoring overall genome instability to detect cancer can be found in literature involving telomere length and the overall chromosomal aberration rate [102,103,104,105,106,107]. More aneuploidy data should be integrated into this effort. In particular, since chromosome data (CIN statuses, for example) have much more clinical predictive power than sequenced gene mutation data [4, 50,51,52,53, 74], bioinformaticians should be encouraged to search for new platforms for mining sequences in the context of evolutionary potential, through the use of AI (artificial intelligence) approaches. For example, this strategy could be used to search for the principle of how aneuploidy changes the blueprint, its overall impact on the gene network, and the quantitative contribution of elements for the higher level of emergence.

Further research is also needed to compare emergence based on average profiles and outliers with various degrees of system stress. Such analysis needs to be done within the context of the cellular society concept [4, 108]. As for the technical platforms, new monitoring methods should be developed to study single cells, especially to profile non-dividing cell populations. Recently, the CRISPR/Cas9 system has been used to eliminate targeted chromosomes. This new approach offers an effective way to develop animal models with aneuploidy, which can be used as a potential therapeutic strategy for human aneuploidy diseases [109]. Certainly, among these advances, one immediate priority is to illustrate how aneuploidy triggers structural alterations of the karyotype and provides the maximal diversity and plasticity needed for new system emergence and domination. For example, can aneuploidy lead to genome chaos [110]? How does the heterogeneity of aneuploidy impact the newly emergent karyotype?

Finally, and perhaps most importantly, the ultimate goal of establishing better concepts and platforms for cancer research is to apply them in the clinic. Further studies are needed to apply this new understanding of aneuploidy for patient stratification, directing therapy schedules, and predicting drug resistance.

Abbreviations

CCA:

clonal chromosome aberrations

C-Frags:

chromosome fragmentations

CIN:

chromosomal instability

CNV:

copy number variations

DMFs:

defective mitotic figures

NCCA:

non clonal chromosome aberrations

References

  1. 1.

    Boveri T. Concerning the origin of malignant tumors. J Cell Sci. 2008; 121: Suppl1, 1–84.

  2. 2.

    Holland AJ, Cleveland DW. Boveri revisited: chromosomal instability, aneuploidy and tumorigenesis. Nature Rev Mol Cell Biol. 2009;10:478–87.

  3. 3.

    Rasnick D. The chromosomal imbalance theory of cancer: the autocatalyzed progression of aneuploidy is carcinogenesis: CRC Press; 2011.

  4. 4.

    Heng HH. Debating Cancer. The paradox in Cancer research. New Jersey: World Scientific Publishing Company; 2015.

  5. 5.

    Mitelman F. Recurrent chromosome aberrations in cancer. Mutat Res. 2000;462:247–53.

  6. 6.

    Heng HH, Stevens JB, Liu G, Bremer SW, Ye KJ, Reddy PV, et al. Stochastic cancer progression driven by nonclonal chromosome aberrations. J Cell Physiol. 2006;208:461–72.

  7. 7.

    Heng HH, et al. Cancer progression by non-clonal chromosome aberrations. J Cell Biochem. 2006;98(6):1424–35.

  8. 8.

    Heng HH, et al. Clonal and non-clonal chromosome aberrations and genome variation and aberration. Genome. 2006;49(3):195–204.

  9. 9.

    Vargas-Rondón N, Villegas VE, Rondón-Lagos M. The Role of Chromosomal Instability in Cancer and Therapeutic Responses. Cancers (Basel). 2017;10(1): pii: E4.

  10. 10.

    Hall JG. Somatic mosaicism: observations related to clinical genetics. Am J Hum Genet. 1988;43:355–63.

  11. 11.

    Yurov YB, et al. Aneuploidy and confined chromosomal mosaicism in the developing human brain. PLoS One. 2007;2:e558.

  12. 12.

    Astolfi PA, Salamini F, Sgaramella V. Are we genomic mosaics? Variations of the genome of somatic cells can contribute to diversify our phenotypes. Curr Genomics. 2010;11(6):379–86.

  13. 13.

    Sgaramella V. The hypergenome in inheritance and development. Cytogenet Genome Res. 2013;139(3):215–22.

  14. 14.

    Heng HH. The contribution of genomic heterogeneity. Preface. Cytogenet Genome Res. 2013;139(3):141–3.

  15. 15.

    Heng HH, Liu G, Stevens JB, Abdallah BY, Horne SD, Ye KJ, et al. Karyotype heterogeneity and unclassified chromosomal abnormalities. Cytogenet Genome Res. 2013;139(3):144–57.

  16. 16.

    Heng HH, Liu G, Stevens JB, Bremer SW, Ye KJ, Abdallah BY, et al. Decoding the genome beyond sequencing: the next phase of genomic research. Genomics. 2011;98(4):242–52.

  17. 17.

    Heng HH. Challenges and new strategies for gulf war illness research. Environ Dis. 2016;1:118–25.

  18. 18.

    Heng HH, Regan S, Ye CJ. Genotype, environment and evolutionary mechanism of diseases. Environ Dis. 2016;1:14–23.

  19. 19.

    Heng HH, Liu G, Regan S, Ye CJ. Chapter 7, Linking Gulf War Illness to genome instability, somatic evolution and complex adaptive systems. In Putting systems and complexity sciences into practice, J. P. Sturmberg (ed). Switzerland: Springer, Cham ; 2018. p. 83–95.

  20. 20.

    Ambartsumyan G, Clark AT. Aneuploidy and early human embryo development. Hum Mol Genet. 2008;17(R1):R10–5.

  21. 21.

    Rehen SK, et al. Chromosomal variation in neurons of the developing and adult mammalian nervous system. Proc Natl Acad Sci U S A. 2001;98:13361–6.

  22. 22.

    Lee A, Kiessling AA. Early human embryos are naturally aneuploid—can that be corrected. J Assist Reprod Genet. 2017;34:15–21.

  23. 23.

    Li R, Yerganian G, Duesberg P, Kraemer A, Willer A, Rausch C, Hehlmann R. Aneuploidy correlated 100% with chemical transformation of Chinese hamster cells. Proc Natl Acad Sci U S A. 1997;94(26):14506–11.

  24. 24.

    Duesberg P, Rausch C, Rasnick D, Hehlmann R. Genetic instability of cancer cells is proportional to their degree of aneuploidy. Proc Natl Acad Sci U S A. 1998;95(23):13692–7.

  25. 25.

    Duesberg P, Rasnick D, Li R, Winters L, Rausch C, Hehlmann R. How aneuploidy may cause cancer and genetic instability. Anticancer Res. 1999;19(6A):4887–906.

  26. 26.

    Duesberg P, Li R, Fabarius A, Hehlmann R. Aneuploidy and cancer: from correlation to causation. Contrib Microbiol. 2006;13:16–44.

  27. 27.

    Wiener F, Klein G, Harris H. The analysis of malignancy by cell fusion. VI. Hybrids between different tumour cells. J Cell Sci. 1974;16(1):189–98.

  28. 28.

    Guan XY, Zhang HE, Zhou H, Sham JS, Fung JM, Trent JM. Characterization of a complex chromosome rearrangement involving 6q in a melanoma cell line by chromosome microdissection. Cancer Genet Cytogenet. 2002;134(1):65–70.

  29. 29.

    Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature. 1998;396(6712):643–9.

  30. 30.

    Gibbs WW. Untangling the roots of cancer. Sci Am. 2003;289(1):56–65.

  31. 31.

    Hanks S, Coleman K, Reid S, Plaja A, Firth H, Fitzpatrick D, et al. Constitutional aneuploidy and cancer predisposition caused by biallelic mutations in BUB1B. Nat Genet. 2004;36(11):1159–61.

  32. 32.

    Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, Qi Y, et al. Detection of large-scale variation in the human genome. Nat Genet. 2004;36:949–51.

  33. 33.

    Sebat J, Lakshmi B, Troge J, Alexander J, Young J, Lundin P, et al. Large-scale copy number polymorphism in the human genome. Science. 2004;305:525–8.

  34. 34.

    Feuk L, Carson AR, Scherer SW. Structural variation in the human genome. Nat Rev Genet. 2006;7(2):85–97.

  35. 35.

    Liehr T. Cytogenetically visible copy number variations (CG-CNVs) in banding and molecular cytogenetics of human; about heteromorphisms and euchromatic variants. Mol Cytogenet. 2016;22:9–5.

  36. 36.

    Liehr T, Cirkovic S, Lalic T, Guc-Scekic M, de Almeida C, Weimer J, et al. Complex small supernumerary marker chromosomes - an update. Mol Cytogenet. 2013;6:46.

  37. 37.

    Heng HH. Genome chaos: rethinking genetics, evolution and molecular medicine (in press). Academic Press.

  38. 38.

    Torres EM, et al. Effects of aneuploidy on cellular physiology and cell division in haploid yeast. Science. 2007;317:916–24.

  39. 39.

    Sheltzer JM, et al. Aneuploidy drives genomic instability in yeast. Science. 2011;333:1026–30.

  40. 40.

    Siegel JJ, Amon A. New insights into the troubles of aneuploidy. Annu Rev Cell Dev Biol. 2012;28:189–214.

  41. 41.

    Zhu J, Pavelka N, Bradford WD, Rancati G, Li R. Karyotypic determinants of chromosome instability in aneuploid budding yeast. PLoS Genet. 2012;8:e1002719.

  42. 42.

    Bonney ME, Moriya H, Amon A. Aneuploid proliferation defects in yeast are not driven by copy number changes of a few dosage-sensitive genes. Genes Dev. 2015;29(9):898–903.

  43. 43.

    Pavelka N, Rancati G, Li R. Dr Jekyll and Mr Hyde: role of aneuploidy in cellular adaptation and cancer. Curr Opin Cell Biol. 2010;22:809–15.

  44. 44.

    Gordon DJ, Resio B, Pellman D. Causes and consequences of aneuploidy in cancer. Nat Rev Genet. 2012;13:189–203.

  45. 45.

    Weaver BA, Silk AD, Montagna C, Verdier-Pinard P, Cleveland DW. Aneuploidy acts both oncogenically and as a tumor suppressor. Cancer Cell. 2007;11:25–36.

  46. 46.

    Weaver BA, Cleveland DW. The aneuploidy paradox in cell growth and tumorigenesis. Cancer Cell. 2008;14:431–3.

  47. 47.

    Gao C, Su Y, Koeman J, Haak E, Dykema K, Essenberg C, et al. Chromosome instability drives phenotypic switching to metastasis. Proc Natl Acad Sci U S A. 2016;113(51):14793–8.

  48. 48.

    Bloomfield M, Duesberg P. Inherent variability of cancer-specific aneuploidy generates metastases. Mol Cytogenet. 2016;9:90.

  49. 49.

    Heng HH. Cancer genome sequencing: the challenges ahead. BioEssays. 2007;29(8):783–94.

  50. 50.

    Heng HH, Bremer SW, Stevens JB, Horne SD, Liu G, Abdallah BY, et al. Chromosomal instability (CIN): what it is and why it is crucial to cancer evolution. Cancer Metastasis Rev. 2013;32(3–4):325–40.

  51. 51.

    Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, et al. Tracking the evolution of non-small-cell lung Cancer. N Engl J Med. 2017;376(22):2109–21.

  52. 52.

    Davoli T, Uno H, Wooten EC, Elledge SJ. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science. 2017;355(6322). pii: eaaf8399.

  53. 53.

    Zanetti M. Chromosomal chaos silences immune surveillance. Science. 2017;355(6322):249–50.

  54. 54.

    Ye CJ, Stevens JB, Liu G, Bremer SW, Jaiswal AS, Ye KJ, et al. Genome based cell population heterogeneity promotes tumorigenicity: the evolutionary mechanism of cancer. J Cell Physiol. 2009;219:288–300.

  55. 55.

    Horne SD, Pollick SA, Heng HH. Evolutionary mechanism unifies the hallmarks of cancer. Int J Cancer. 2015;136(9):2012–21.

  56. 56.

    Heng HH, Stevens JB, Bremer SW, Liu G, Abdallah BY, Ye CJ. Evolutionary mechanisms and diversity in cancer. Adv Cancer Res. 2011;112:217–53.

  57. 57.

    Heng HH. The conflict between complex systems and reductionism. JAMA. 2008;300(13):1580–1.

  58. 58.

    Coffey DS. Self-organization, complexity and chaos: the new biology for medicine. Nat Med. 1998;4(8):882–5.

  59. 59.

    Heng HH. The genomic landscape of cancers (chapter 5) in ecology and evolution of Cancer, eds Ujvari, Roche, Thomas (eds). Acadmic Press, 2017. Pp69–86.

  60. 60.

    Hernandez D, Fisher EM. Mouse autosomal trisomy: two's company, three's a crowd. Trends Genet. 1999;15(6):241–7.

  61. 61.

    Valind A, Jin Y, Baldetorp B, Gisselsson D. Whole chromosome gain does not in itself confer cancer-like chromosomal instability. Proc Natl Acad Sci U S A. 2013;110(52):21119–23.

  62. 62.

    Heng HH. Distinguishing constitutional and acquired nonclonal aneuploidy. Proc Natl Acad Sci U S A. 2014;111(11):E972.

  63. 63.

    Duesberg P, Rasnick D. Aneuploidy, the somatic mutation that makes cancer a species of its own. Cell Motil Cytoskeleton. 2000;47(2):81–107.

  64. 64.

    Ye CJ, Liu G, Bremer SW, Heng HH. The dynamics of cancer chromosomes and genomes. Cytogenet Genome Res. 2007;18:237–46.

  65. 65.

    Vincent MD. The animal within: carcinogenesis and the clonal evolution of cancer cells are speciation events sensu stricto. Evolution. 2010;64(4):1173–83.

  66. 66.

    Heng HH. The genome-centric concept: resynthesis of evolutionary theory. BioEssays. 2009;31(5):512–25.

  67. 67.

    Liu G, Stevens JB, Horne SD, Abdallah BY, Ye KJ, Bremer SW, et al. Genome chaos: survival strategy during crisis. Cell Cycle. 2014;13(4):528–37.

  68. 68.

    Horne SD, Ye CJ, Abdallah BY, Liu G, Heng HH. Cancer genome evolution. Transl Cancer Res. 2015;4(3):303–13.

  69. 69.

    Heng HH, Regan S. A systems biology perspective on molecular cytogenetics. Cur bioinformatics. 2017;12:4–10.

  70. 70.

    Heng HH, Horne SD, Chaudhry S, Regan SM, Liu G, Abdallah BY, Ye CJ. A Postgenomic Perspective on Molecular Cytogenetics. Cur Genomics. 2018;19(3):227–39.

  71. 71.

    Wang Y, Waters J, Leung ML, Unruh A, Roh W, Shi X, et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature. 2014;512:155–60.

  72. 72.

    Abdallah BY, Horne SD, Stevens JB, Liu G, Ying AY, Vanderhyden B, et al. Single cell heterogeneity: why unstable genomes are incompatible with average profiles. Cell Cycle. 2013;12(23):3640–9.

  73. 73.

    Abdallah BY, Horne SD, Kurkinen M, Stevens JB, Liu G, Ye CJ, et al. Ovarian cancer evolution through stochastic genome alterations: defining the genomic role in ovarian cancer. Syst Biol Reprod Med. 2014;60(1):2–13.

  74. 74.

    Heng HH, Regan SM, Liu G, Ye CJ. Why it is crucial to analyze non clonal chromosome aberrations or NCCAs? Mol Cytogenet. 2016;9:15.

  75. 75.

    Heng HH, Stevens JB, Bremer SW, Ye KJ, Liu G, Ye CJ. The evolutionary mechanism of cancer. J Cell Biochem. 2010;109(6):1072–84.

  76. 76.

    Sheltzer JM, Torres EM, Dunham MJ, Amon A. Transcriptional consequences of aneuploidy. Proc Natl Acad Sci U S A. 2012;109(31):12644–9.

  77. 77.

    Zhang H, Yang X, Feng X, Xu H, Yang Q, et al. Chromosome-wide gene dosage rebalance may benefit tumor progression. Mol Genet Genomics. 2018; https://doi.org/10.1007/s00438-018-1429-2. [Epub ahead of print].

  78. 78.

    Heng HH, Stevens JB, Liu G, Bremer SW, Ye CJ. Imaging genome abnormalities in cancer research. Cell Chromosome. 2004;3(1):1.

  79. 79.

    Heng HH. Elimination of altered karyotypes by sexual reproduction preserves species identity. Genome. 2007;50(5):517–24.

  80. 80.

    Wilkins AS, Holliday R. The evolution of meiosis from mitosis. Genetics. 2009;181(1):3–12.

  81. 81.

    Gorelick R, Heng HH. Sex reduces genetic variation: a multidisciplinary review. Evolution. 2011;65(4):1088–98.

  82. 82.

    Horne SD, Abdallah BY, Stevens JB, Liu G, Ye KJ, Bremer SW, Heng HH. Genome constraint through sexual reproduction: application of 4D-Genomics in reproductive biology. Syst Biol Reprod Med. 2013;59(3):124–30.

  83. 83.

    Rancati G, Pavelka N, Fleharty B, Noll A, Trimble R, Walton K, et al. Aneuploidy underlies rapid adaptive evolution of yeast cells deprived of a conserved cytokinesis motor. Cell. 2008;135(5):879–93.

  84. 84.

    Loeb LA. Human Cancers Express a Mutator Phenotype: Hypothesis, Origin, and Consequences. Cancer Res. 2016;76(8):2057–9.

  85. 85.

    Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, Drier Y, et al. Punctuated evolution of prostate cancer genomes. Cell. 2013;153(3):666–77.

  86. 86.

    Notta F, Chan-Seng-Yue M, Lemire M, Li Y, Wilson GW, Connor AA, et al. A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. Nature. 2016;538(7625):378–82.

  87. 87.

    Sun R, Hu Z, Curtis C. Big Bang Tumor Growth and Clonal Evolution. Cold Spring Harb Perspect Med. 2017; pii: a028381.

  88. 88.

    Markowetz F. A saltationist theory of cancer evolution. Nat Genet. 2016;48(10):1102–3. https://doi.org/10.1038/ng.3687.

  89. 89.

    Chandrakasan S, Ye CJ, Chitlur M, Mohamed AN, Rabah R, Konski A, et al. Malignant fibrous histiocytoma two years after autologous stem cell transplant for Hodgkin lymphoma: evidence for genomic instability. Pediatr Blood Cancer. 2011;56(7):1143–5.

  90. 90.

    Eichler EE, Flint J, Gibson G, Kong A, Leal SM, Moore JH, et al. Missing heritability and strategies for finding the underlying causes of complex disease. Nat Rev Genet. 2010;11(6):446–50.

  91. 91.

    Heng HH. Missing heritability and stochastic genome alterations. Nat Rev Genet. 2010;11:813.

  92. 92.

    Horne SD, Chowdhury SK, Heng HH. Stress, genomic adaptation, and the evolutionary trade-off. Front Genet. 2014;5:92.

  93. 93.

    Stevens JB, Abdallah BY, Liu G, Ye CJ, Horne SD, Wang G, et al. Diverse system stresses: common mechanisms of chromosome fragmentation. Cell Death Dis. 2011;2:e178.

  94. 94.

    Heng HH, Horne SD, Stevens JB, Abdallah BY, Liu G, Chowdhury SK, Et. al. chapter 9, heterogeneity mediated system complexity: the ultimate challenge for studying common and complex diseases. The value of systems and complexity sciences for healthcare. Joachin P Sturmberg (eds). New York: Springer, 2016. p101–115.

  95. 95.

    Cimini D, Tanzarella C, Degrassi F. Differences in malsegregation rates obtained by scoring ana-telophases or binucleate cells. Mutagenesis. 1999;14(6):563–8.

  96. 96.

    Thompson SL, Compton DA. Examining the link between chromosomal instability and aneuploidy in human cells. J Cell Biol. 2008;180(4):665–72.

  97. 97.

    Milena Dürrbaum and Zuzana Storchová Effects of aneuploidy on gene expression: implications for cancer. The FEBS Journal. 2016; 283: 791–802.

  98. 98.

    Heng HH. Heterogeneity-mediated cellular adaptation and its trade-off: searching for the general principles of diseases. J Eval Clin Pract. 2017 Feb;23(1):233–7.

  99. 99.

    Tomasetti C, Vogelstein B. Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science. 2015;347:78–81.

  100. 100.

    Tomasetti C, Li L, Vogelstein B. Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention. Science. 2017;355(6331):1330–4.

  101. 101.

    Park SY, Gönen M, Kim HJ, Michor F, Polyak K. Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J Clin Invest. 2010 Feb;120(2):636–44.

  102. 102.

    Barrios L, Caballin MR, Miro R, Fuster C, Guedea F, Subias A, et al. Chromosomal instability in breast cancer patients. Hum Genet. 1991;88:39–41.

  103. 103.

    Bonassi S, Hagmar L, Stromberg U, Montagud AH, Tinnerberg H, Forni A, et al. Chromosomal aberrations in lymphocytes predict human cancer independently of exposure to carcinogens. European study group on cytogenetic biomarkers and health. Cancer Res. 2000;60:1619–25.

  104. 104.

    El-Zein R, Gu Y, Sierra MS, Spitz MR, Strom SS. Chromosomal instability in peripheral blood lymphocytes and risk of prostate cancer. Cancer Epidemiol Biomark Prev. 2005;14:748–52.

  105. 105.

    Hagmar L, Bonassi S, Stromberg U, Mikoczy Z, Lando C, Hansteen IL, et al. Cancer predictive value of cytogenetic markers used in occupational health surveillance programs. Recent Results Cancer Res. 1998;154:177–84.

  106. 106.

    Heng HQ, Chen WY, Wang YC. Effects of pingyanymycin on chromosomes: a possible structural basis for chromosome aberration. Mutat Res. 1988;199(1):199–205.

  107. 107.

    Hsu TC. Genetic instability in the human population: a working hypothesis. Hereditas. 1983;98:1–9.

  108. 108.

    Heppner GH. Cancer cell societies and tumor progression. Stem Cells. 1993;11(3):199–203.

  109. 109.

    Zuo E, Huo X, Yao X, Hu X, Sun Y, Yin J, et al. CRISPR/Cas9-mediated targeted chromosome elimination. Genome Biol. 2017 Nov 24;18(1):224. https://doi.org/10.1186/s13059-017-1354.

  110. 110.

    Ye CJ, Liu G, Heng HH. Chapter 21: experimental induction of genome chaos. Chromothripsis: methods and protocols, 2018 springer, Ed frank Pellestor. Methods Mol Biol. 2018;1769:337–52.

  111. 111.

    Solomon et al. Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science. 2011;333:1039–43.

  112. 112.

    Sansregret L, Swanton C. The Role of Aneuploidy in Cancer Evolution. Cold Spring Harb Perspect Med. 2017;7(1). pii: a028373.

  113. 113.

    Roussel-Gervais A, Naciri I, Kirsh O, Kasprzyk L, Velasco G, Grillo G, et al. Loss of the methyl-CpG-binding protein ZBTB4 alters mitotic checkpoint, increases aneuploidy, and promotes tumorigenesis. Cancer Res. 2017;77(1):62–73.

  114. 114.

    Giam M, Rancati G. Aneuploidy and chromosomal instability in cancer: a jackpot to chaos. Cell Div. 2015;10:3.

  115. 115.

    Schvartzman JM, Duijf PH, Sotillo R, Coker C, Benezra R. Mad2 is a critical mediator of the chromosome instability observed upon Rb and p53 pathway inhibition. Cancer Cell. 2011;19:701–14.

  116. 116.

    Ganem NJ, Godinho SA, Pellman D. A mechanism linking extra centrosomes to chromosomal instability. Nature. 2009;460:278–82.

  117. 117.

    Shen KC, Heng H, Y Wang SL, Liu G, Deng CX, Brooks SC, Wang YA. ATM and p21 cooperate to suppress aneuploidy and subsequent tumor development. Cancer Res. 2005;65(19):8747–53.

  118. 118.

    Stevens JB, Liu G, Bremer SW, Ye KJ, Xu W, Xu J, et al. Mitotic cell death by chromosome fragmentation. Cancer Res. 2007;67(16):7686–94.

  119. 119.

    Ohashi A, Ohori M, Iwai K, Nakayama Y, Nambu T, et al. Aneuploidy generates proteotoxic stress and DNA damage concurrently with p53-mediated post-mitotic apoptosis in SAC-impaired cells. Nat. Commun. 2015; 6:7668.

  120. 120.

    Potopova TA, Zhu J, Li R. Aneuploidy and chromosomal instability: a vicious cycle driving cellular evolution and cancer genome chaos. Cancer Metastasis Rev. 2013;32(3–4):377–89.

  121. 121.

    Heng HH, Bremer WS, Stevens JB, Ye KJ, Liu G, Ye CJ, et al. Genetic and epigenetic heterogeneity in Cancer: a genome centric perspective. J Cell Physiol. 2009;220(3):538–47.

  122. 122.

    Stevens JB, Liu G, Abdallah BY, Horne SD, Ye KJ, Bremer SW, et al. Unstable genomes elevate transcriptome dynamics. Int J Cancer. 2014;134(9):2074–87.

  123. 123.

    Stevens JB, Horne SD, Abdallah BY, Ye CJ, Heng HH. Chromosomal instability and transcriptome dynamics in cancer. Cancer Metastasis Rev. 2013 Dec;32(3–4):391–402.

  124. 124.

    Schukken KM, Foijer F. CIN and aneuploidy: different concepts, different consequences. BioEssays. 2018;40(1)

  125. 125.

    Walen KH. Budded karyoplasts from multinucleated fibroblast cells contain centrosomes and change their morphology to mitotic cells. Cell Biol Int. 2005;29(12):1057–65.

  126. 126.

    Erenpreisa J, Cragg MS. MOS, aneuploidy, and the ploidy cycle of cancer cells. Oncogene. 2010;29(40):5447–51.

  127. 127.

    Zhang S, Mercado-Uribe I, Sun B, Kuang J, Liu J. Generation of cancer-stem-like cells through the formation of polyploid giant cancer cells. Oncogene. 2014;33(1):116–28.

  128. 128.

    Hultén MA, Jonasson J, Iwarsson E, Uppal P, Vorsanova SG, Yurov YB, et al. Trisomy 21 mosaicism: we may all have a touch of Down syndrome. Cytogenet Genome Res. 2013;139(3):189–92.

  129. 129.

    Iourov IY, Vorsanova SG, Yurov YB. Chromsomal mosaicism goes global. Mol Cytogenet. 2008;1:26.

  130. 130.

    Vidotto T, Tiezzi DG, Squire JA. Distinct subtypes of genomic PTEN deletion size influence the landscape of aneuploidy and outcome in prostate cancer. Mol Cytogenet. 2018;11(1)

  131. 131.

    Santaguida S, Richardson A, Iyer DR, M'Saad O, Zasadil L, Knouse KA, et al. Chromosome Mis-segregation Generates Cell-Cycle-Arrested Cells with Complex Karyotypes that Are Eliminated by the Immune System. Dev Cell. 2017;41(6):638–651.e5.

  132. 132.

    Rutledge SD, Cimini D. Consequences of aneuploidy in sickness and in health. Curr Opin Cell Biol. 2016;40:41–6.

  133. 133.

    Santaguida S, Amon A. Short- and long-term effects of chromosome mis-segregation and aneuploidy. Nat Rev Mol Cell Biol. 2015;16(8):473–85.

  134. 134.

    Sheltzer JM, Ko JH, Replogle JM, Habibe Burgos NC, Chung ES, et al. Single-chromosome Gains Commonly Function as Tumor Suppressors. Cancer Cell. 2017;31(2):240–55.

  135. 135.

    Herrera LA, Prada D, Andonegui MA, Dueñas-González A. The epigenetic origin of aneuploidy. Curr Genomics. 2008;9(1):43–50.

  136. 136.

    Davidsson J. The epigenetic landscape of aneuploidy: constitutional mosaicism leading the way. Epigenomics. 2014;6(1):45–58.

  137. 137.

    Mulla WA, Seidel CW, Zhu J, Tsai HJ, Smith SE, Singh P et al., Aneuploidy as a cause of impaired chromatin silencing and mating-type specification in budding yeast. Elife. 2017;6. pii: e27991.

  138. 138.

    Heng HH. Bio-complexity: Challenging reductionism. In: Sturmberg JP, Martin CM, editors. Handbook on systems and complexity in health. New York: Springer; 2013. p. 193–208.

  139. 139.

    Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.

Download references

Acknowledgements

This manuscript is part of our series of publications on the subject of “the mechanisms of cancer and organismal evolution.” This work was also partially supported by the start-up fund for Christine J. Ye from the University of Michigan’s Department of Internal Medicine, Hematology/Oncology Division. We thank Dr. Emanuela Volpi, the special issue editor, for her kind invitation. We also thank two anonymous reviewers for their valuable suggestions, and Julie Heng for partial editing.

Funding

This work was partially supported by the start-up fund for CJY from the department of internal medicine, division of hematology/oncology, University of Michigan.

Availability of data and materials

Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

Author information

CY and HH drafted the manuscript. SR, GL and SA contributed to discussion and editing. All authors read and approved the final manuscript.

Correspondence to Henry H. Heng.

Ethics declarations

Ethics approval and consent to participate

N/A

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ye, C.J., Regan, S., Liu, G. et al. Understanding aneuploidy in cancer through the lens of system inheritance, fuzzy inheritance and emergence of new genome systems. Mol Cytogenet 11, 31 (2018) doi:10.1186/s13039-018-0376-2

Download citation

Keywords

  • Adaptive system
  • Aneuploidy
  • Cancer evolution
  • Complexity
  • Emergence of new genome
  • Fuzzy inheritance
  • Genome theory
  • Non-clonal chromosome aberrations (NCCAs)
  • Punctuated evolution
  • System inheritance